Hi Mark,
No doubt Australian investors generally struggle to look outside our own backyard, and appropriately value the global potential.
Also worth having a look at Dexcom (DXCM on the Nasdaq) - circa $40 billion USD market cap, on about $1.5bn USD revenue in 2019.
They have done for diabetes what Respiri is attempting to do for asthma.
It is those that can see the bigger picture that will make the big $$ with this stock IMO.
Hi Mark, No doubt Australian investors generally struggle to...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.54M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 800000 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 508500 | 3 |
View Market Depth
| Last trade - 16.12pm 11/09/2024 (20 minute delay) ? |
| RSH (ASX) Chart |
Day chart unavailable